Investigator Initiated Study (IIS)

Dermavant supports investigator/externally led research programs related to disease areas of interest related to Dermavant’s compounds.

The objectives of these programs are to:

  • Advance clinical and pre-clinical research
  • Generate health outcomes data and real-world evidence
  • Enhance disease understanding

These programs are open to physicians, researchers and institutions interested in conducting external research.

Investigators and/or their affiliated institutions and networks assume responsibility for all aspects of the study, including design, regulatory submission, initiation, conduct, and monitoring of the research, along with data analysis and communication (e.g. abstract, manuscript, and final study report) of the results.

Proposals submitted to Dermavant are reviewed by Dermavant's scientific and medical committees. Approval of a proposal is based on scientific merit, patient safety considerations, unmet medical need, study design, availability of resources, and feasibility of study conduct. Support for approved proposals may be provided in the form of study drug supply, funding, or both depending on the request, and is contingent upon a final approved protocol, regulatory clearance, Investigator Review Board approval, and full execution of a research agreement.

Please submit all IIS proposals and / or inquiries via email at iis@dermavant.com